Aemetis (NASDAQ:AMTX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aemetis (NASDAQ:AMTX - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $28.00 price objective on the specialty chemicals company's stock.

AMTX has been the topic of several other research reports. UBS Group cut their target price on Aemetis from $8.25 to $7.75 and set a "buy" rating on the stock in a research report on Monday, August 19th. StockNews.com upgraded shares of Aemetis to a "sell" rating in a research note on Wednesday, July 31st. Truist Financial reiterated a "hold" rating and set a $3.50 price target (down previously from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. Finally, Ascendiant Capital Markets cut their target price on shares of Aemetis from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Aemetis has an average rating of "Moderate Buy" and a consensus price target of $12.95.

Aemetis Stock Down 5.9 %

Shares of AMTX traded down $0.24 during midday trading on Friday, hitting $3.83. The company's stock had a trading volume of 713,435 shares, compared to its average volume of 806,729. The stock has a market capitalization of $190.50 million, a price-to-earnings ratio of -1.69 and a beta of 1.23. Aemetis has a one year low of $2.10 and a one year high of $7.03. The company's fifty day simple moving average is $2.80 and its two-hundred day simple moving average is $3.06.

Aemetis (NASDAQ:AMTX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. The company had revenue of $81.44 million during the quarter, compared to analyst estimates of $77.79 million. During the same quarter in the previous year, the company earned ($0.59) earnings per share. On average, research analysts predict that Aemetis will post -2.1 earnings per share for the current year.

Institutional Trading of Aemetis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMTX. SG Americas Securities LLC bought a new position in Aemetis in the first quarter worth about $60,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Aemetis during the 1st quarter valued at about $84,000. Bank of New York Mellon Corp bought a new position in Aemetis in the second quarter worth approximately $306,000. Rhumbline Advisers raised its holdings in Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company's stock worth $157,000 after purchasing an additional 50,528 shares during the period. Finally, Hutchinson Capital Management CA bought a new position in shares of Aemetis in the second quarter worth about $70,000. Hedge funds and other institutional investors own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.